GlaxoSmithKline
United States
3326 articles about GlaxoSmithKline
-
In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA's decisions in 2024.
-
Sosei Heptares Regains Full Ownership from GSK of HTL0027477, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease
3/21/2024
Sosei Group Corporation announces it has regained full ownership from GSK of HTL0027477, a clinic-ready, highly selective, first-in-class, oral GPR35 agonist in development as a potential new treatment for Inflammatory Bowel Diseases.
-
New late-stage trial results for GSK’s Jemperli show improved overall and progression-free survival in a broader range of endometrial cancer patients, which could lead to a potential label expansion.
-
Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer
3/16/2024
GSK plc announced statistically significant and clinically meaningful overall survival results from Part 1 and progression-free survival results from Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial in adult patients with primary advanced or recurrent endometrial cancer.
-
The antibody-drug conjugate beat the standard of care in second-line multiple myeloma, the company reported on Thursday, as it seeks to get the cancer drug back on the U.S. market.
-
The World Health Organization has detected signals of growing HIV resistance to GSK and ViiV Healthcare’s Tivicay, which it says must be minimized as part of the broader global response to antimicrobial resistance.
-
The FDA and CDC warned Thursday of a small increased risk of developing Guillain-Barré syndrome in older adults after immunization with respiratory syncytial virus vaccines from GSK and Pfizer.
-
The oral antibiotic, which is also in development for uncomplicated urinary tract infections, demonstrated non-inferiority to the most common treatment for gonorrhea.
-
GSK terminated their collaboration with Vir to research, develop and commercialize the biotech’s monoclonal antibodies for the prevention, treatment, or prophylaxis of the influenza under a 2021 agreement.
-
ViiV Healthcare and GSK’s Cabenuva in a Phase III study showed superior efficacy versus daily oral antiretroviral treatment in HIV patients with a history of difficulties in taking daily pills.
-
23andMe Reports Third Quarter Fiscal 2024 Financial Results
2/7/2024
23andMe Holding Co., a leading human genetics and biopharmaceutical company, reported its financial results for the third quarter of fiscal year 2024, which ended December 31, 2023.
-
The antibody-drug conjugate, in combination with Takeda’s Velcade and the steroid dexamethasone, reduced the risk of death and disease progression by 59% versus a similar Darzalex-based regimen.
-
ViiV Healthcare announces new packaging option now available in the U.S. for Dovato (dolutegravir/lamivudine)
2/5/2024
ViiV Healthcare announced Dovato is now available in a blister pack in the U.S. Dovato is approved as a complete regimen to treat HIV-1 infection in adults with no antiretroviral treatment history or to replace the current ARV regimen in those who are virologically suppressed on a stable ARV regimen with no history of treatment failure and no known resistance to any component of Dovato.
-
The British pharma expects “meaningful” sales and earnings growth in 2024 and is upgrading its growth outlooks for 2026 and 2031, according to GSK CEO Emma Walmsley.
-
The British drugmaker on Wednesday said it sold around 300 million shares of Haleon, cutting its shareholding to 4.2%, as it expands its portfolio of specialty medicines, Reuters reported.
-
Following the J.P. Morgan Healthcare Conference and other parallel meetings in San Francisco, it’s time to reflect on some of the significant deals secured last week.
-
Following in the footsteps of Novartis, J&J and Merck, GSK jumped into the J.P. Morgan dealmaking frenzy Tuesday, picking up respiratory and inflammation-focused Aiolos Bio.
-
GSK Enters Agreement to Acquire Aiolos Bio
1/9/2024
GSK plc and Aiolos Bio, Inc. announced that they have entered into an agreement under which GSK will acquire Aiolos, a clinical-stage biopharmaceutical company focused on addressing the unmet treatment needs of patients with certain respiratory and inflammatory conditions, for a $1 billion upfront payment and up to $400 million in certain success-based regulatory milestone payments.
-
The Alliance for Genomic Discovery welcomes Bristol Myers Squibb, GSK, and Novo Nordisk
1/4/2024
Illumina Inc. in collaboration with Nashville Biosciences, LLC, a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center, announced three new members of the Alliance for Genomic Discovery.
-
GSK withdrew three patents related to its asthma inhalers while Impax delisted both of its patents for Adrenaclick and Kaléo delisted eight patents covering Auvi-Q—the companies’ respective epinephrine auto-injectors.